secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001104659-23-104304
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM
--------------------------------------------------------------------------------

- Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.
- Interim analysis of progression-free survival anticipated after sufficient events from the 120 subjects.
- Sagimet expects FASCINATE-2 Phase 2b NASH biopsy results and Phase 1 hepatic impairment data in Q1 2024.
- Denifanstat is an oral FASN inhibitor; Sagimet licensed China rights to Ascletis in January 2019.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/0001104659-23-104304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/tm2327008d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-104304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer